A pilot phase II protocol of arsenic trioxide (TRISENOX) in subjects with advanced carcinoma of the breast.

Trial Profile

A pilot phase II protocol of arsenic trioxide (TRISENOX) in subjects with advanced carcinoma of the breast.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Arsenic trioxide (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2013 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top